Auris Medical Holding AG (NASDAQ:EARS) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 648,081 shares, a decrease of 31.3% from the November 15th total of 943,665 shares. Currently, 2.7% of the shares of the stock are short sold. Based on an average daily volume of 2,302,699 shares, the short-interest ratio is presently 0.3 days.

Separately, Zacks Investment Research cut Auris Medical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th.

Auris Medical (NASDAQ:EARS) opened at $0.46 on Thursday. Auris Medical has a fifty-two week low of $0.38 and a fifty-two week high of $1.39. The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of -14.04.

A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned approximately 0.32% of Auris Medical as of its most recent SEC filing. 25.15% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/auris-medical-holding-ag-ears-short-interest-update/1775395.html.

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.